Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Zosano PharmaCohBarMerrimack PharmaceuticalsVascular BiogenicsAeterna Zentaris
SymbolNASDAQ:ZSANNASDAQ:CWBRNASDAQ:MACKNASDAQ:VBLTNASDAQ:AEZS
Price Information
Current Price$0.81$1.12$7.32$1.74$0.85
52 Week RangeBuyBuyN/ABuyN/A
MarketRank™
Overall Score1.41.51.11.30.6
Analysis Score3.53.50.03.50.0
Community Score2.93.32.92.42.9
Dividend Score0.00.00.00.00.0
Ownership Score0.00.82.50.00.0
Earnings & Valuation Score0.60.00.00.60.0
Analyst Ratings
Consensus RecommendationBuyBuyN/ABuyN/A
Consensus Price Target$2.17$5.50N/A$4.13N/A
% Upside from Price Target168.05% upside391.07% upsideN/A137.07% upsideN/A
Trade Information
Market Cap$99.49 million$70.44 million$101.78 million$85.77 million$57.04 million
Beta2.982.962.551.172.1
Average Volume10,132,435683,15891,1951,000,79718,200,803
Sales & Book Value
Annual RevenueN/AN/AN/A$560,000.00$530,000.00
Price / SalesN/AN/AN/A149.72100.55
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.40 per share$0.19 per share$1.30 per share$1.00 per share($0.12) per share
Price / BookN/AN/AN/A1.74-7.09
Profitability
Net Income$-37,590,000.00$-13,050,000.00$-17,330,000.00$-19,460,000.00$-6,040,000.00
EPS($2.29)($0.30)N/A($0.54)N/A
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/A-2,692.41%-369.10%
Return on Equity (ROE)-227.55%-124.02%-14.94%-61.77%-125.54%
Return on Assets (ROA)-79.80%-80.21%-12.96%-47.23%-21.45%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.16%N/AN/AN/A
Current Ratio0.68%10.26%8.42%5.16%12.98%
Quick Ratio0.68%10.26%8.42%5.16%12.77%
Ownership Information
Institutional Ownership Percentage10.07%10.20%52.25%4.50%2.44%
Insider Ownership Percentage6.10%39.36%21.60%N/AN/A
Miscellaneous
Employees5611273812
Shares Outstanding106.29 million61.79 million13.41 million48.19 million62.68 million
Next Earnings Date5/13/2021 (Estimated)5/13/2021 (Estimated)5/6/2021 (Estimated)5/13/2021 (Estimated)5/5/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Aeterna Zentaris Inc. (NASDAQ:AEZS) Stock Could Reward Investors With a 411.36% GainAeterna Zentaris Inc. (NASDAQ:AEZS) Stock Could Reward Investors With a 411.36% Gain
marketingsentinel.com - April 19 at 1:12 PM
Analysts think Aeterna Zentaris Inc. (NASDAQ:AEZS) could rise 411.36% from current levelsAnalysts think Aeterna Zentaris Inc. (NASDAQ:AEZS) could rise 411.36% from current levels
stocksregister.com - April 19 at 1:12 PM
Aeterna Zentaris Inc. (NASDAQ:AEZS) Short Interest UpdateAeterna Zentaris Inc. (NASDAQ:AEZS) Short Interest Update
americanbankingnews.com - April 15 at 1:48 AM
Aeterna Zentaris Inc. [AEZS] Stock trading around $0.94 per share: What’s Next?Aeterna Zentaris Inc. [AEZS] Stock trading around $0.94 per share: What’s Next?
dbtnews.com - April 13 at 6:38 PM
AEterna Zentaris Stock Shows Every Sign Of Being Significantly OvervaluedAEterna Zentaris Stock Shows Every Sign Of Being Significantly Overvalued
finance.yahoo.com - April 13 at 7:33 AM
What Do Wall Street Analysts Think About Aeterna Zentaris Inc. (NASDAQ:AEZS) Stock?What Do Wall Street Analysts Think About Aeterna Zentaris Inc. (NASDAQ:AEZS) Stock?
stocksregister.com - April 13 at 1:00 AM
Why should you add Aeterna Zentaris Inc. (AEZS) to your portfolio?Why should you add Aeterna Zentaris Inc. (AEZS) to your portfolio?
marketingsentinel.com - April 12 at 9:59 AM
Critical Analysis: Trillium Therapeutics (NASDAQ:TRIL) & Aeterna Zentaris (NASDAQ:AEZS)Critical Analysis: Trillium Therapeutics (NASDAQ:TRIL) & Aeterna Zentaris (NASDAQ:AEZS)
americanbankingnews.com - April 8 at 12:20 PM
Aeterna Zentaris (NASDAQ:AEZS) Share Price Crosses Above 200 Day Moving Average of $0.69Aeterna Zentaris (NASDAQ:AEZS) Share Price Crosses Above 200 Day Moving Average of $0.69
americanbankingnews.com - April 3 at 12:36 AM
Should Aeterna Zentaris (TSE:AEZS) Be Disappointed With Their 100% Profit?Should Aeterna Zentaris (TSE:AEZS) Be Disappointed With Their 100% Profit?
finance.yahoo.com - March 30 at 8:07 AM
If You’re Not Bullish on Aeterna Zentaris Inc. (NASDAQ:AEZS) Now, You’ll Kick Yourself LaterIf You’re Not Bullish on Aeterna Zentaris Inc. (NASDAQ:AEZS) Now, You’ll Kick Yourself Later
stocksregister.com - March 29 at 10:25 AM
Analysts Say Aeterna Zentaris Inc. (NASDAQ:AEZS) Can Really Get to $4.5 in 12 MonthsAnalysts Say Aeterna Zentaris Inc. (NASDAQ:AEZS) Can Really Get to $4.5 in 12 Months
marketingsentinel.com - March 26 at 12:05 PM
Aeterna Zentaris Inc. [AEZS] Stock trading around $1.18 per share: What’s Next?Aeterna Zentaris Inc. [AEZS] Stock trading around $1.18 per share: What’s Next?
dbtnews.com - March 26 at 7:05 AM
Analysts Say You Should Buy Your Position in Aeterna Zentaris Inc. (NASDAQ:AEZS)Analysts Say You Should Buy Your Position in Aeterna Zentaris Inc. (NASDAQ:AEZS)
stocksregister.com - March 26 at 12:53 AM
Aeterna Zentaris: Q4 Earnings SnapshotAeterna Zentaris: Q4 Earnings Snapshot
finance.yahoo.com - March 25 at 9:50 AM
Aeterna Zentaris: Q4 Earnings Snapshot | Raleigh News & ObserverAeterna Zentaris: Q4 Earnings Snapshot | Raleigh News & Observer
newsobserver.com - March 25 at 9:50 AM
Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial ResultsAeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 25 at 9:50 AM
Analyzing The Price Action In AEterna Zentaris Stock TodayAnalyzing The Price Action In AEterna Zentaris Stock Today
msn.com - March 15 at 2:51 PM
Aeterna Zentaris Shares Are Trading Higher On Announcing Licensing Pact For Development Of Prophylactic COVID-19 Vaccine CandidateAeterna Zentaris Shares Are Trading Higher On Announcing Licensing Pact For Development Of Prophylactic COVID-19 Vaccine Candidate
finance.yahoo.com - March 15 at 2:51 PM
AEZS Stock Price Increases Over 10% Pre-Market: Why It HappenedAEZS Stock Price Increases Over 10% Pre-Market: Why It Happened
pulse2.com - March 15 at 9:51 AM
Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with ...Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with ...
apnews.com - March 15 at 9:51 AM
Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COVID-19Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COVID-19
finance.yahoo.com - March 15 at 9:51 AM
Stocks in play: Aeterna Zentaris IncStocks in play: Aeterna Zentaris Inc
ca.finance.yahoo.com - March 11 at 12:42 PM
Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary HypoparathyroidismAeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism
finance.yahoo.com - March 11 at 12:42 PM
Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences ConferenceAeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - February 24 at 12:38 PM
DateCompanyBrokerageAction
3/22/2021Zosano PharmaMaxim GroupBoost Price Target
11/25/2020Zosano PharmaHC WainwrightLower Price Target
10/22/2020Zosano PharmaBTIG ResearchLower Price Target
11/15/2019Zosano PharmaCantor FitzgeraldLower Price Target
3/31/2021CohBarAegisReiterated Rating
3/31/2021CohBarChardan CapitalBoost Price Target
11/10/2020CohBarRoth CapitalReiterated Rating
10/15/2020CohBarWBB SecuritiesInitiated Coverage
5/28/2020CohBarBrookline Capital ManagementInitiated Coverage
11/7/2018Merrimack PharmaceuticalsCowenReiterated Rating
10/20/2018Merrimack PharmaceuticalsRobert W. BairdSet Price Target
6/25/2018Merrimack PharmaceuticalsJPMorgan Chase & Co.Downgrade
5/14/2020Vascular BiogenicsOppenheimerReiterated Rating
6/27/2019Vascular BiogenicsCIBCInitiated Coverage
(Data available from 4/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.